In a sealed 25 mL round-bottom flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methoxy-1-methyl-ethyl)-amide (32 mg, 0.061 mmol) and TFA (0.9 ml, 11.7 mmol) were combined with dichloromethane (3 ml) to give an orange solution. The reaction mixture was stirred at room temperature until the consumption of starting material (2.5 h). The reaction mixture was then concentrated under reduced pressure. The resultant crude solid was dissolved in dichloromethane (3 mL) and ethylenediamine (300 μl, 4.44 mmol) was added. The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was concentrated and the residue was precipitated with water. The suspension was stirred for 1 h and the crude solid collected by filtration. The crude solid was purified by trituration (1:1 dichloromethane/heptane) to afford 14 mg (59%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methoxy-1-methyl-ethyl)-amide as an off-white solid. MS: [M+H]+=399; 1H NMR (300 MHz, DMSO-d6) δ: 9.11 (s, 1H), 8.53 (d, J=8.6 Hz, 1H), 8.44 (s, 1H), 8.20 (d, J=8.6 Hz, 1H), 8.01 (d, J=1.5 Hz, 1H), 7.28 (dd, J=8.6, 2.0 Hz, 1H), 4.30-4.46 (m, 1H), 4.18 (s, 3H), 3.53 (dd, J=9.6, 5.1 Hz, 1H), 3.47 (dd, J=9.6, 4.5 Hz, 1H), 3.27 (s, 3H), 1.31 (d, J=6.6 Hz, 3H).
